AKTX

Akari Therapeutics
AKTX

Overview Fund Activity

13 hedge funds and large institutions have $16.2M invested in Akari Therapeutics in 2014 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
13
Holders Change
+4
Holders Change %
+44.44%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Franklin Resources
Franklin Resources
California
+$3.86M
2
SM
Sabby Management
Florida
+$831K
3
HighTower Advisors
HighTower Advisors
Illinois
+$186K
4
PCM
Prelude Capital Management
New York
+$12K
5
TRCT
Tower Research Capital (TRC)
New York
+$6.43K

Top Sellers

1
KCM
Knoll Capital Management
Florida
-$49.4K
2
Citigroup
Citigroup
New York
-$11K
Name Holding Trade Value Shares
Change 		Shares
Change %
SM
1
Sabby Management
Florida
$4.51M +$831K +755 +23%
Franklin Resources
2
Franklin Resources
California
$3.86M +$3.86M +3,509 New
BBA
3
Baker Bros. Advisors
New York
$3.71M – – –
BC
4
Broadfin Capital
New York
$2.92M – – –
CAM
5
Cormorant Asset Management
Massachusetts
$639K – – –
DCM
6
DAFNA Capital Management
California
$272K – – –
HighTower Advisors
7
HighTower Advisors
Illinois
$186K +$186K +150 New
KCM
8
Knoll Capital Management
Florida
$78K -$49.4K -45 -39%
PCM
9
Prelude Capital Management
New York
$12K +$12K +10 New
TRCT
10
Tower Research Capital (TRC)
New York
$9K +$6.43K +5 +250%
U
11
UBS
Switzerland
$6K +$3.6K +3 +150%
GSC
12
Ground Swell Capital
South Carolina
$3K +$3K +3 New
Citigroup
13
Citigroup
New York
$1K -$11K -11 -92%